<?xml version="1.0" encoding="UTF-8"?>
<p id="Par45">Lopinavir, a protease inhibitor, has also been tested in COVID-19 treatment. It is used combined with ritonavir, which inhibits CYP-3A-mediated metabolism of lopinavir. Previous reports showed that lopinavir/ritonavir had improved clinical outcomes in SARS and MERS patients [
 <xref ref-type="bibr" rid="CR108">108</xref>]. In a recent, randomized-controlled trial in hospitalized adult COVID-19 patients (99 patients in lopinavir/ritonavir group versus 100 in standard care group), Cao et al. reported that no benefit was associated with lopinavir/ritonavir treatment beyond standard care [
 <xref ref-type="bibr" rid="CR109">109</xref>]. Ongoing trials will provide further data regarding the efficacy and safety of lopinavir/ritonavir in COVID-19 treatment (e.g., ChiCTR2000029609; NCT04261907).
</p>
